13F Data
13F filer · CIK 1845151

MWG Management Ltd.

Washington, DC · filing since Q4 2020 · last filing Nov 12, 2025
Reported value
$81.3M
+$29.4M vs prior
Positions
3
New / sold out
1 / 1
Added / reduced
0 / 0
Turnover
13.4%
buys $16.4M · sells $8.9M
Top-10 weight
100.0%

Biggest buys vs Q2 2025

ChangeSecurityShares changeChange %Est. trade value
NewLYELL IMMUNOPHARMA INC+1,008,116–+$16.4M

Biggest sells vs Q2 2025

ChangeSecurityShares changeChange %Est. trade value
Sold outLYELL IMMUNOPHARMA INC-1,008,116-100.0%$-8.9M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2020: $157.7KQ1 2021: $205.8MQ2 2021: $1.0BQ3 2021: $824.7MQ4 2021: $343.1MQ1 2022: $236.3MQ2 2022: $222.3MQ3 2022: $259.6MQ4 2022: $195.9MQ1 2023: $142.0MQ2 2023: $165.3MQ3 2023: $103.2MQ4 2023: $118.9MQ1 2024: $135.1MQ2 2024: $91.6MQ3 2024: $90.3MQ4 2024: $74.4MQ1 2025: $58.7MQ2 2025: $51.9MQ3 2025: $81.3M
Q4 2020Q3 2025

Holdings · Q3 2025

#SecuritySharesValueWeight
1BEAM THERAPEUTICS INCCOM2,266,934$55.0M67.66%
2LYELL IMMUNOPHARMA INCCOM NEW1,008,116$16.4M20.13%
3PRIME MEDICINE INCCOM1,792,210$9.9M12.21%